A

Alexion

Global biopharmaceuticals focusing on rare diseases

Clinical Research Associate

Full-TimeUpdated on 10/15/2026
No salary listed
Junior
Bachelor's
Seoul, South Korea
In Person
Biology & BiotechClinical Research Operations

About the job

Requirements
  • At least 1 year of clinical research associate monitoring experience.
  • A bachelor's degree in a related discipline, preferably life science, or an equivalent qualification.
  • Excellent knowledge of International Council for Harmonisation Good Clinical Practice guidelines and basic knowledge of Good Manufacturing Practice and Good Distribution Practice.
  • Excellent knowledge of relevant local regulations.
  • Good medical knowledge and ability to learn the relevant therapeutic areas.
  • Good understanding of the drug development process.
  • Excellent understanding of clinical study management, including monitoring, study drug handling, and data management.
  • Demonstrates excellent attention to detail, written and verbal communication, collaboration, interpersonal skills, and negotiation skills.
  • Demonstrates flexibility in schedule and willingness to travel; required travel may be as high as 70% during busy periods.
  • Must be able, with or without accommodation, to use a computer; communicate via phone, video, and electronic messaging; engage in problem solving and non-linear thought, analysis, and dialogue; collaborate with others; and maintain general availability during standard business hours.
  • Excellent written and verbal communication skills in both English and the local language.
  • Must have no restriction preventing overseas travel.
Responsibilities
  • Perform site identification, selection, initiation, monitoring, site data review, and closeout activities and visits, both remote and onsite, as well as remote data checks, within the timelines in the study-specific Clinical Monitoring Plan.
  • Drive site performance, proactively identify and ensure timely resolution of study-related issues, and escalate issues as appropriate.
  • Train, support, and advise investigators and site staff on study-related matters, including Risk Based Quality Management principles.
  • Develop recruitment plans with each site and manage and support enrollment to meet site and study milestones; document recruitment barriers and implement mitigation plans.
  • Ensure agreed monitoring key performance indicators remain within agreed quality-acceptable ranges, including action-item aging, source data verification metrics, data-entry metrics, query aging, and monitoring-visit-report metrics.
  • Prepare and finalize monitoring visit reports in the clinical trial management system and provide timely feedback and follow-up letters to the principal investigator within required timelines and in line with standard operating procedures.
  • Ensure timely collection and upload of essential documents into the electronic trial master file in accordance with International Council for Harmonisation Good Clinical Practice, standard operating procedures, and local requirements; support or participate in regular quality-control checks of the electronic trial master file.
  • In some countries, perform study start-up and regulatory maintenance, including collecting, preparing, reviewing, and tracking application documents and submitting applications and documents to ethics committees or institutional review boards and regulatory authorities for study start-up and duration.
  • Contribute to nominating and selecting potential investigators and assist with feasibility activities.
  • Collaborate with local Medical Affairs, Medical Advisor Pipeline, and other internal stakeholders as needed.
  • Follow quality-issue processes by escalating systematic or serious quality issues, data privacy breaches, or Good Clinical Practice compliance issues to the global study team, local study team, country operations line management, and/or quality group representatives as required.
  • Prepare for and collaborate on audit and regulatory inspection activities with local team members, including project management clinical operations, country operations line management, and quality group representatives.
Desired Qualifications
  • Ability to work with remote collaborators and in a matrix reporting structure.
  • Manage change positively for oneself, the team, and the business, and identify opportunities to improve performance and add business value.
  • Identify and champion more efficient and effective processes for delivering quality clinical trials with reduced budgets and in less time.
  • Prioritize and manage multiple tasks with conflicting deadlines.
  • Communicate proactively and assertively with internal stakeholders and study sites.
  • Understand the impact of technology on projects and use and develop computer skills while appropriately using systems and software in an electronically enabled environment.
  • Be team-oriented and flexible, and respond quickly to shifting demands and opportunities.
  • Experience across all study phases and in rare medical conditions.
  • A Good Clinical Practice or work-related certificate.

About the company

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Flexible Work Hours

Remote Work Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Stock Options

Company Equity

401(k) Retirement Plan

Mental Health Support

Wellness Program

Gym Membership

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Training Programs

Tuition Reimbursement

Professional Certification Support

Mentorship Program

Parental Leave

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Relocation Assistance

Employee Referral Bonus

Meal Benefits

Commuter Benefits

Legal Services

Employee Discounts

Company Social Events

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old